Medicine
Symfi 600 mg/300 mg/300 mg tablet
Symfi 600 mg/300 mg/300 mg tablet is a prescription medicine containing Efavirenz, Lamivudine and Tenofovir disoproxil for oral use, marketed by Viatris Specialty, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30°C (86°F).
Key facts
- Active ingredient (INN)
- Efavirenz, Lamivudine and Tenofovir disoproxil
- Brand
- Symfi
- Strength
- 600 mg/300 mg/300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Viatris Specialty
- Manufacturer
- Viatris Specialty
- Origin register
- US FDA, United States
- Storage
- Store below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 April 2018
- Identifiers
- RxCUI 864661, 2043464DailyMed set ID 81a55dd9-78a8-49c3-88ab-8f5bffafa359NDC 49502-475Application NDA022142
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, plastic in 1 carton / 30 tablet, film coated in 1 bottle, plastic | 49502-475-93 | Viatris Specialty | 25 April 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 February 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Efavirenz, Lamivudine and Tenofovir disoproxil 600 mg/300 mg/300 mg tablet.
Other strengths and forms of Efavirenz, Lamivudine and Tenofovir disoproxil
Clinical summary
Efavirenz, Lamivudine and Tenofovir disoproxil is a fixed-dose combination of a hepatitis B virus nucleoside analog reverse transcriptase inhibitor, a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor and a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Efavirenz, Lamivudine and Tenofovir disoproxil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Efavirenz, Lamivudine and Tenofovir disoproxilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SYMFI prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
Need Symfi 600 mg/300 mg/300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.